Telavancin for Injection (Vibativ)
برای این دارو، اطلاعات عمومی (فارسی) یافت نشد . برای افزودن اطلاعات فارسی به این دارو کلیک نمایید.
Telavancin for Injection (Vibativ)

VIBATIV
(telavancin) for Injection, for Intravenous Use

WARNING: FETAL RISK

  • Women of childbearing potential should have a serum pregnancy test prior to administration of VIBATIV (telavancin for injection)
  • Avoid use of VIBATIV (telavancin for injection) during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus
  • Adverse developmental outcomes observed in 3 animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans [see WARNINGS AND PRECAUTIONS, Use in Specific Populations]

DRUG DESCRIPTION

VIBATIV contains telavancin hydrochloride, a lipoglycopeptide antibacterial that is a synthetic derivative of vancomycin. The chemical name of telavancin hydrochloride is vancomycin,N3”-[2-(decylamino)ethyl]-29-[[(phosphono-methyl)-amino]-methyl]- hydrochloride. Telavancin hydrochloride has the following chemical structure:

Figure 1 : Telavancin Hydrochloride

VIBATIV (telavancin hcl) Structural Formula Illustration

Telavancin hydrochloride is an off-white to slightly colored amorphous powder with the empirical formula C80H106C12N11O27P•xHCl (where x = 1 to 3) and a free-base molecular weight of 1755.6. It is highly lipophilic and slightly soluble in water.

VIBATIV (telavancin for injection) is a sterile, preservative-free, white to slightly colored lyophilized powder containing telavancin hydrochloride (equivalent to either 250 mg or 750 mg of telavancin as the free base) for intravenous use. The inactive ingredients are Hydroxypropylbetadex, Ph. Eur (hydroxypropyl-beta-cyclodextrin) (2500 mg per 250 mg telavancin, 7500 mg per 750 mg telavancin), mannitol (312.5 mg per 250 mg telavancin, 937.5 mg per 750 mg telavancin), and sodium hydroxide and hydrochloric acid used in minimal quantities for pH adjustment. When reconstituted, it forms a clear to slightly colored solution with a pH of 4.5 (4.0 to 5.0).

What are the possible side effects of telavancin (Vibativ)?

Some people receiving a telavancin injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your doctor right away if you feel itchy or tingly, or have a red rash on your upper body during the injection.

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • diarrhea that is watery or bloody;
  • drowsiness, confusion, mood changes, increased...

Read All Potential Side Effects and See Pictures of Vibativ »

What are the precautions when taking telavancin for injection (Vibativ)?

Before using telavancin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, diabetes, high blood pressure (hypertension).

Telavancin may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can infrequently result in serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that require immediate medical attention. The risk of QT prolongation may be increased if you have certain medical conditions or are...

Read All Potential Precautions of Vibativ »

Last reviewed on RxList: 9/17/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV (telavancin for injection) and other antibacterial drugs, VIBATIV (telavancin for injection) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Complicated Skin and Skin Structure Infections

VIBATIV (telavancin for injection) is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), or Enterococcus faecalis (vancomycin-susceptible isolates only).

Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative organisms.

Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to telavancin. VIBATIV (telavancin for injection) may be initiated as empiric therapy before results of these tests are known.

DOSAGE AND ADMINISTRATION

Complicated Skin and Skin Structure Infections

The recommended dosing for VIBATIV (telavancin for injection) is 10 mg/kg administered over a 60-minute period in patients ≥ 18 years of age by intravenous infusion once every 24 hours for 7 to 14 days. The duration of therapy should be guided by the severity and site of the infection and the patient's clinical and bacteriological progress.

Patients with Renal Impairment

Because telavancin is eliminated primarily by the kidney, a dosage adjustment is required for patients whose creatinine clearance is ≤ 50 mL/min, as listed in Table 1 [see CLINICAL PHARMACOLOGY].

Table 1 : Dosage Adjustment in Adult Patients with Renal Impairment

Creatinine Clearance* (mL/min) VIBATIV Dosage Regimen
> 50 10 mg/kg every 24 hours
30 - 50 7.5 mg/kg every 24 hours
10 - ≤ 30 10 mg/kg every 48 hours
* As calculated using the Cockcroft-Gault formula [see CLINICAL PHARMACOLOGY]

There is insufficient information to make specific dosage adjustment recommendations for patients with end-stage renal disease (CrCl < 10 mL/min), including patients undergoing hemodialysis.

Preparation and Administration

250 mg vial: Reconstitute the contents of a VIBATIV (telavancin for injection) 250 mg vial with 15 mL of 5% Dextrose Injection, USP; Sterile Water for Injection, USP; or 0.9% Sodium Chloride Injection, USP. The resultant solution has a concentration of 15 mg/mL (total volume of approximately 17.0 mL).

750 mg vial: Reconstitute the contents of a VIBATIV (telavancin for injection) 750 mg vial with 45 mL of 5% Dextrose Injection, USP; Sterile Water for Injection, USP; or 0.9% Sodium Chloride Injection, USP, The resultant solution has a concentration of 15 mg/mL (total volume of approximately 50.0 mL).

The following formula can be used to calculate the volume of reconstituted VIBATIV solution required to prepare a dose:

Telavancin dose (mg) = 10 mg/kg or 7.5 mg/kg x patient weight (in kg) (see Table 1)

Volume of reconstituted solution (mL) = Telavancin dose (mg)/ 15 mg/mL

For doses of 150 to 800 mg, the appropriate volume of reconstituted solution must be further diluted in 100 to 250 mL prior to infusion. Doses less than 150 mg or greater than 800 mg should be further diluted in a volume resulting in a final concentration of 0.6 to 8 mg/mL. Appropriate infusion solutions include: 5% Dextrose Injection, USP; 0.9% Sodium Chloride Injection, USP; or Lactated Ringer's Injection, USP. The dosing solution should be administered by intravenous infusion over a period of 60 minutes.

Reconstitution time is generally under 2 minutes, but can sometimes take up to 20 minutes. Mix thoroughly to reconstitute and check to see if the contents have dissolved completely. Parenteral drug products should be inspected visually for particulate matter prior to administration. Discard the vial if the vacuum did not pull the diluent into the vial.

Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparing the final intravenous solution. Studies have shown that the reconstituted solution in the vial should be used within 4 hours when stored at room temperature or within 72 hours under refrigeration at 2 to 8° C (36 to 46° F). The diluted (dosing) solution in the infusion bag should be used within 4 hours when stored at room temperature or used within 72 hours when stored under refrigeration at 2 to 8° C (36 to 46° F). However, the total time in the vial plus the time in the infusion bag should not exceed 4 hours at room temperature and 72 hours under refrigeration at 2 to 8° C (36 to 46° F).

VIBATIV (telavancin for injection) is administered intravenously. Because only limited data are available on the compatibility of VIBATIV (telavancin for injection) with other IV substances, additives or other medications should not be added to VIBATIV (telavancin for injection) single-use vials or infused simultaneously through the same IV line. If the same intravenous line is used for sequential infusion of additional medications, the line should be flushed before and after infusion of VIBATIV (telavancin for injection) with 5% Dextrose Injection, USP; 0.9% Sodium Chloride Injection, USP; or Lactated Ringer's Injection, USP.

HOW SUPPLIED

Dosage Forms And Strengths

VIBATIV (telavancin for injection) is supplied in single-use vials containing either 250 or 750 mg telavancin as a sterile, lyophilized powder.

Storage And Handling

Cartons of 10 individually packaged 250 mg single-dose vials
(NDC 0469-3525-30)

Cartons of 10 individually packaged 750 mg single-dose vials
(NDC 0469-3575-50)

Store original packages at refrigerated temperatures of 2 to 8°C (35 to 46 °F). Excursions to ambient temperatures (up to 25°C (77 °F)) are acceptable. Avoid excessive heat.

Manufactured for: Theravance, Inc., South San Francisco, CA 94080, Marketed by: Astellas Pharma US, Inc. Deerfield, IL 60015.

Last reviewed on RxList: 9/17/2009
This monograph has been modified to include the generic and brand name in many instances.

SIDE EFFECTS

The following serious adverse reactions are discussed elsewhere in the labeling:

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience

The two Phase 3 cSSSI clinical trials (Trial 1 and Trial 2) for VIBATIV (telavancin for injection) included 929 adult patients treated with VIBATIV (telavancin for injection) at 10 mg/kg IV once daily. The mean age of patients treated with VIBATIV (telavancin for injection) was 49 years (range 18-96). There was a slight male predominance (56%) in patients treated with VIBATIV (telavancin for injection) , and patients were predominantly Caucasian (78%).

In the cSSSI clinical trials, < 1% (8/929) patients who received VIBATIV (telavancin for injection) died and < 1% (8/938) patients treated with vancomycin died. Serious adverse events were reported in 7% (69/929) of patients treated with VIBATIV (telavancin for injection) and most commonly included renal, respiratory, or cardiac events. Serious adverse events were reported in 5% (43/938) of vancomycin-treated patients, and most commonly included cardiac, respiratory, or infectious events. Treatment discontinuations due to adverse events occurred in 8% (72/929) of patients treated with VIBATIV (telavancin for injection) , the most common events being nausea and rash (~1% each). Treatment discontinuations due to adverse events occurred in 6% (53/938) of vancomycin-treated patients, the most common events being rash and pruritus (~1% each).

The most common adverse reactions occurring in 10% of VIBATIV (telavancin for injection) -treated patients observed in the VIBATIV (telavancin for injection) Phase 3 cSSSI trials were taste disturbance, nausea, vomiting, and foamy urine.

Table 4 displays the incidence of treatment-emergent adverse drug reactions reported in > 2% of patients treated with VIBATIV (telavancin for injection) possibly related to the drug (including those reactions known to occur with other glycopeptide antibacterial agents).

Table 4: Incidence of Treatment-emergent Adverse Drug Reactions Reported in ≥ 2% of VIBATIV (telavancin for injection) or Vancomycin Patients Treated in Trial 1 and Trial 2

  VIBATIV
(N=929)
Vancomycin
(N=938)
Body as a Whole
  Rigors 4% 2%
  Generalized pruritus 3% 6%
Digestive System
  Nausea 27% 15%
  Vomiting 14% 7%
  Diarrhea 7% 8%
  Abdominal pain 2% 2%
Metabolic and Nutritional
  Decreased appetite 3% 2%
Nervous System
  Taste disturbance1 33% 7%
  Dizziness 6% 6%
Renal System
  Foamy urine 13% 3%
Skin and Appendages
  Pruritus 6% 13%
  Rash 4% 5%
Other
  Infusion site pain 4% 4%
  Infusion site erythema 3% 3%
1Described as a metallic or soapy taste.

Read the Vibativ (telavancin for injection) Side Effects Center for a complete guide to possible side effects »

DRUG INTERACTIONS

Drug-Laboratory Test Interactions

Effects of Telavancin on Coagulation Test Parameters

Telavancin binds to the artificial phospholipid surfaces added to common anticoagulation tests, thereby interfering with the ability of the coagulation complexes to assemble on the surface of the phospholipids and promote clotting in vitro. These effects appear to depend on the type of reagents used in commercially available assays. Thus, when measured shortly after completion of an infusion of VIBATIV (telavancin for injection) , increases in the PT, INR, aPTT, and ACT have been observed. These effects dissipate over time, as plasma concentrations of telavancin decrease.

Urine Protein Tests

Telavancin interferes with urine qualitative dipstick protein assays, as well as quantitative dye methods (e.g., pyrogallol red-molybdate). However, microalbumin assays are not affected and can be used to monitor urinary protein excretion during VIBATIV (telavancin for injection) treatment.

Last reviewed on RxList: 9/17/2009
This monograph has been modified to include the generic and brand name in many instances.

WARNINGS

Included as part of the PRECAUTIONS section.

PRECAUTIONS

Women of Childbearing Potential

Women of childbearing potential should have a serum pregnancy test prior to administration of VIBATIV (telavancin for injection) . If not already pregnant, women of childbearing potential should use effective contraception during VIBATIV (telavancin for injection) treatment.

Pregnancy

Avoid use of VIBATIV (telavancin for injection) during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus. VIBATIV (telavancin for injection) caused adverse developmental outcomes in 3 animal species at clinically relevant doses. This raises concern about potential adverse developmental outcomes in humans [see Use in Specific Populations].

Nephrotoxicity

Increases in serum creatinine to 1.5 times baseline occurred more frequently among VIBATIV (telavancin for injection) -treated patients with normal baseline serum creatinine (15%) compared with vancomycin-treated patients with normal baseline serum creatinine (7%).

In 30/929 (3.1%) of VIBATIV (telavancin for injection) -treated patients compared to 10/938 (1.1%) of vancomycin-treated patients, renal adverse events indicative of renal impairment occurred, as defined by the following terms: increased serum creatinine, renal impairment, renal insufficiency, and/or renal failure. In 17 of the 30 VIBATIV (telavancin for injection) -treated patients, these adverse events had not completely resolved by the end of the trials, compared with 6 of the 10 vancomycin-treated patients. Serious adverse events indicative of renal impairment occurred in 11/929 (1.2%) of VIBATIV (telavancin for injection) -treated patients compared to 3/938 (0.3%) of vancomycin-treated patients. Twelve patients treated with VIBATIV (telavancin for injection) discontinued treatment due to adverse events indicative of renal impairment compared to 2 patients treated with vancomycin. Adverse events were more likely to occur in patients with baseline comorbidities known to predispose patients to kidney dysfunction (pre-existing renal disease, diabetes mellitus, congestive heart failure, or hypertension). The renal adverse event rate was also higher in patients who received concomitant medications known to affect kidney function (eg, non-steroidal antiinflammatory drugs, ACE inhibitors, and loop diuretics). Fifteen of 174 patients (8.6%) ≥ 65 years of age had adverse events indicative of renal impairment compared to 16 of 755 patients (1.9%) < 65 years of age [see Use in Specific Populations].

Monitor renal function (i.e., serum creatinine, creatinine clearance) in all patients receiving VIBATIV (telavancin for injection) . Values should be obtained prior to initiation of treatment, during treatment (at 48- to 72-hour intervals or more frequently, if clinically indicated), and at the end of therapy. If renal function decreases, the benefit of continuing VIBATIV (telavancin for injection) versus discontinuing and initiating therapy with an alternative agent should be assessed [see DOSAGE AND ADMINISTRATION, CLINICAL PHARMACOLOGY].

In patients with renal dysfunction, accumulation of the solubilizer hydroxypropyl-beta-cyclodextrin can occur [see Patients with Renal Impairment and CLINICAL PHARMACOLOGY].

Decreased Efficacy with Moderate/Severe Baseline Renal Impairment

In a subgroup analysis of the pooled cSSSI studies, clinical cure rates in the telavancin-treated patients were lower in patients with baseline CrCl 50 mL/min compared to those with CrCl > 50 mL/min (Table 2). A decrease of this magnitude was not observed in vancomycin-treated patients. Consider these data when selecting antibacterial therapy for use in patients with baseline moderate/severe renal impairment.

Table 2: Clinical Cure by Baseline Renal Function

  VIBATIV
% (n/N)
Vancomycin
% (n/N)
ATe Population1
  CrCl>50 mL/min 75.3% (565/750) 73.7% (575/780)
  CrCl ≤ 50 mL/min 63.1% (70/111) 69.4% (75/108)
CE Population2
  CrCl>50 mL/min 87.0% (520/598) 85.9% (524/610)
  CrCl ≤ 50 mL/min 67.4% (58/86) 82.7% (67/81)
1 All-treated population - includes all patients randomized, treated, and evaluated for efficacy
2 Clinically evaluable population

Infusion-Related Reactions

VIBATIV (telavancin for injection) is a lipoglycopeptide antibacterial agent and should be administered over a period of 60 minutes to reduce the risk of infusion-related reactions. Rapid intravenous infusions of the glycopeptide class of antimicrobial agents can cause “Red-man Syndrome”-like reactions including: flushing of the upper body, urticaria, pruritus, or rash. Stopping or slowing the infusion may result in cessation of these reactions.

Clostridium difficile-Associated Diarrhea

Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the flora of the colon and may permit overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hyper-toxin-producing strains of C. difficile cause increased morbidity and mortality, since these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Development of Drug-Resistant Bacteria

Prescribing VIBATIV (telavancin for injection) in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

As with other antibacterial drugs, use of VIBATIV (telavancin for injection) may result in overgrowth of nonsusceptible organisms, including fungi. Patients should be carefully monitored during therapy. If superinfection occurs, appropriate measures should be taken.

QTc Prolongation

In a study involving healthy volunteers, doses of 7.5 and 15 mg/kg of VIBATIV prolonged the QTc interval [see CLINICAL PHARMACOLOGY]. Caution is warranted when prescribing VIBATIV (telavancin for injection) to patients taking drugs known to prolong the QT interval. Patients with congenital long QT syndrome, known prolongation of the QTc interval, uncompensated heart failure, or severe left ventricular hypertrophy were not included in clinical trials of VIBATIV (telavancin for injection) . Use of VIBATIV (telavancin for injection) should be avoided in patients with these conditions.

Coagulation Test Interference

Although telavancin does not interfere with coagulation, it interfered with certain tests used to monitor coagulation (Table 3), when conducted using samples drawn 0 to 18 hours after VIBATIV (telavancin for injection) administration for patients being treated once every 24 hours. Blood samples for these coagulation tests should be collected as close as possible prior to a patient's next dose of VIBATIV (telavancin for injection) . Blood samples for coagulation tests unaffected by VIBATIV may be collected at any time [see DRUG INTERACTIONS].

Table 3 : Coagulation Tests Affected and Unaffected by Telavancin

Affected by Telavancin Unaffected by Telavancin
Prothrombin time
International normalized ratio
Activated partial thromboplastin time
Activated clotting time
Coagulation based factor Xa tests
Thrombin time
Whole blood (Lee-White) clotting time
Ex vivo platelet aggregation
Chromogenic factor Xa assay
Functional (chromogenic) factor X assay
Bleeding time
D-dimer
Fibrin degradation products

No evidence of increased bleeding risk has been observed in clinical trials with VIBATIV. Telavancin has no effect on platelet aggregation. Furthermore, no evidence of hypercoagulability has been seen, as healthy subjects receiving VIBATIV (telavancin for injection) have normal levels of D-dimer and fibrin degradation products.

Patient Counselling Information

See Medication Guide.

Use during Pregnancy and by Women of Childbearing Potential

Women of childbearing potential (those who have not had: complete absence of menses for at least 24 months or medically confirmed menopause, medically confirmed primary ovarian failure, a history of hysterectomy, bilateral oophorectomy, or tubal ligation) should:

  • Be informed about the potential risk of fetal harm if VIBATIV (telavancin for injection) is used during pregnancy
  • Have a pregnancy test prior to administration of VIBATIV (telavancin for injection)
  • If not pregnant, use effective contraceptive methods to prevent pregnancy during VIBATIV (telavancin for injection) treatment
  • Notify their prescribing physician/ healthcare provider if they become pregnant during VIBATIV (telavancin for injection) treatment
Pregnancy Registry

There is a pregnancy registry that monitors pregnancy outcomes in women exposed to VIBATIV (telavancin for injection) during pregnancy. Physicians are encouraged to register pregnant patients, or pregnant women may enroll themselves in the pregnancy registry by calling 1-888-658-4228.

Diarrhea

Diarrhea is a common problem caused by antibiotics that usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having received the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Correct Use of Antibacterial Drugs

Patients should be counseled that antibacterial drugs including VIBATIV (telavancin for injection) should only be used to treat bacterial infections. They do not treat viral infections (eg, the common cold). When VIBATIV (telavancin for injection) is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of immediate treatment, and (2) increase the likelihood that the bacteria will develop resistance and will not be treatable by VIBATIV (telavancin for injection) or other antibacterial drugs in the future.

Common Adverse Effects

Patients should be informed about the common adverse effects of VIBATIV (telavancin for injection) including taste disturbance, nausea, vomiting, headache, and foamy urine. Patients should be instructed to inform their healthcare provider if they develop any unusual symptom, or if any known symptom persists or worsens. Patients should be instructed to inform their healthcare provider of any other medications they are currently taking with VIBATIV (telavancin for injection) , including over-the-counter medications.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to determine the carcinogenic potential of telavancin have not been performed.

Neither mutagenic nor clastogenic potential of telavancin was found in a battery of tests including: assays for mutagenicity (Ames bacterial reversion), an in vitro chromosome aberration assay in human lymphocytes, and an in vivo mouse micronucleus assay.

Telavancin did not affect the fertility or reproductive performance of adult male rats (exposed to telavancin for at least 4 weeks prior to mating) or female rats (exposed to telavancin for at least 2 weeks prior to mating).

Male rats given telavancin for 6 weeks, at exposures similar to those measured in clinical studies, displayed altered sperm parameters that were reversible following an 8-week recovery period.

Use In Specific Populations

Pregnancy

Teratogenic effects: Pregnancy Category C
Pregnancy Exposure Registry

There is a pregnancy registry that monitors pregnancy outcomes in women exposed to VIBATIV (telavancin for injection) during pregnancy. Physicians are encouraged to register pregnant patients, or pregnant women may enroll themselves in the VIBATIV (telavancin for injection) pregnancy registry by calling 1-888-658-4228.

Fetal Risk Summary

All pregnancies have a background risk of birth defects (about 3%), pregnancy loss (about 15%), or other adverse outcomes regardless of drug exposure.

There are no data on VIBATIV (telavancin for injection) use in pregnant women. In 3 animal species, VIBATIV (telavancin for injection) exposure during pregnancy at clinically relevant doses caused reduced fetal weights and increased rates of digit and limb malformations in offspring. These data raise concern about potential adverse developmental outcomes in humans (see Data).

Clinical Considerations

Given the lack of human data and the risks suggested by animal data, avoid using VIBATIV (telavancin for injection) in pregnant women unless the benefits to the patient outweigh the potential risks to the fetus.

Data

Human Data

There are no data on human pregnancies exposed to VIBATIV (telavancin for injection) .

Animal Data

In embryo-fetal development studies in rats, rabbits, and minipigs, telavancin demonstrated the potential to cause limb and skeletal malformations when given intravenously during the period of organogenesis at doses up to 150, 45 or 75 mg/kg/day, respectively. These doses resulted in exposure levels approximately 1- to 2-fold the human exposure (AUC) at the maximum clinical recommended dose. Malformations observed at < 1% (but absent or at lower rates in historical or concurrent controls), included brachymelia (rats and rabbits), syndactyly (rats, minipigs), adactyly (rabbits), and polydactyly (minipigs). Additional findings in rabbits included flexed front paw and absent ulna, and in the minipigs included misshapen digits and deformed front leg. Fetal body weights were decreased in rats.

In a prenatal/perinatal development study, pregnant rats received intravenous telavancin at up to 150 mg/kg/day (approximately the same AUC as observed at the maximum clinical dose) from the start of organogenesis through lactation. Offspring showed decreases in fetal body weight and an increase in the number of stillborn pups. Brachymelia was also observed. Developmental milestones and fertility of the pups were unaffected.

Nursing Mothers

It is not known whether telavancin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when VIBATIV (telavancin for injection) is administered to a nursing woman.

Pediatric Use

The safety and effectiveness of VIBATIV (telavancin for injection) in pediatric patients has not been studied.

Geriatric Use

Of the 929 patients treated with VIBATIV (telavancin for injection) at a dose of 10 mg/kg once daily in clinical trials of cSSSI, 174 (18.7%) were ≥ 65 years of age and 87 (9.4%) were ≥ 75 years of age. In the cSSSI trials, lower clinical cure rates were observed in patients ≥ 65 years of age compared with those < 65 years of age. Overall, treatment-emergent adverse events occurred with similar frequencies in patients ≥ 65 (75% of patients) and < 65 years of age (83% of patients). Fifteen of 174 (8.6%) patients ≥ 65 years of age treated with telavancin had adverse events indicative of renal impairment compared to 16 of 755 (1.9%) patients < 65 years of age [see WARNINGS AND PRECAUTIONS, Clinical Trials].

Telavancin is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in this age group.

The mean plasma AUC values of telavancin were similar in healthy young and elderly subjects. Dosage adjustment for elderly patients should be based on renal function [see DOSAGE AND ADMINISTRATION, CLINICAL PHARMACOLOGY].

Patients with Renal Impairment

The cSSSI trials included patients with normal renal function and patients with varying degrees of renal impairment. Patients with underlying renal dysfunction or risk factors for renal dysfunction had a higher incidence of renal adverse events [see WARNINGS AND PRECAUTIONS]. Patients with creatinine clearance ≤ 50 mL/min also had lower clinical cure rates. Consider these data when selecting antibacterial therapy in patients with baseline moderate/ severe renal impairment (CrCl 50 mL/min).

Dosage adjustment is required in patients with ≤ 50 mL/min renal impairment [see DOSAGE AND ADMINISTRATION]. There is insufficient information to make specific dosage adjustment recommendations for patients with end-stage renal disease (CrCl < 10 mL/min), including patients receiving hemodialysis [see OVERDOSAGE, CLINICAL PHARMACOLOGY].

Hydroxypropyl-beta-cyclodextrin is excreted in urine and may accumulate in patients with renal impairment. Serum creatinine should be closely monitored and, if renal toxicity is suspected, an alternative agent should be considered [see WARNINGS AND PRECAUTIONS, CLINICAL PHARMACOLOGY].

Patients with Hepatic Impairment

The cSSSI trials included patients with normal hepatic function and with hepatic impairment. No dosage adjustment is recommended in patients with mild or moderate hepatic impairment [see CLINICAL PHARMACOLOGY].

Last reviewed on RxList: 9/17/2009
This monograph has been modified to include the generic and brand name in many instances.

OVERDOSE

In the event of overdosage, VIBATIV (telavancin for injection) should be discontinued and supportive care is advised with maintenance of glomerular filtration and careful monitoring of renal function. Following administration of a single dose of VIBATIV (telavancin for injection) 7.5 mg/kg to subjects with end-stage renal disease, approximately 5.9% of the administered dose of telavancin was recovered in the dialysate following 4 hours of hemodialysis. However, no information is available on the use of hemodialysis to treat an overdosage [see CLINICAL PHARMACOLOGY)].

The clearance of telavancin by continuous venovenous hemofiltration (CVVH) was evaluated in an in vitro study [see Nonclinical Toxicology]. Telavancin was cleared by CVVH and the clearance of telavancin increased with increasing ultrafiltration rate. However, the clearance of telavancin by CVVH has not been evaluated in a clinical study; thus, the clinical significance of this finding and use of CVVH to treat an overdosage is unknown.

CONTRAINDICATIONS

None.

Last reviewed on RxList: 9/17/2009
This monograph has been modified to include the generic and brand name in many instances.

CLINICAL PHARMACOLOGY

Mechanism of Action

Telavancin is an antibacterial drug.

Pharmacodynamics

The antimicrobial activity of telavancin appears to best correlate with the ratio of area under the concentration-time curve to minimal inhibitory concentration (AUC/MIC) for Staphylococcus aureus based on animal models of infection. An exposure-response analysis of 2 cSSSI clinical trials supports the dose of 10 mg/kg every 24 hours.

Cardiac Electrophysiology

The effect of telavancin on cardiac repolarization was assessed in a randomized, double-blind, multiple-dose, positive-controlled, and placebo-controlled, parallel study (n=160). Healthy subjects received VIBATIV (telavancin for injection) 7.5 mg/kg, VIBATIV (telavancin for injection) 15 mg/kg, positive control, or placebo infused over 60 minutes once daily for 3 days. Based on interpolation of the data from VIBATIV (telavancin for injection) 7.5 mg/kg and 15 mg/kg, the mean maximum baseline-corrected, placebo-corrected QTc prolongation at the end of infusion was estimated to be 12-15 msec for VIBATIV (telavancin for injection) 10 mg/kg and 22 msec for the positive control (Table 5). By 1 hour after infusion the maximum QTc prolongation was 6-9 msec for VIBATIV (telavancin for injection) and 15 msec for the positive control.

Table 5 : Mean and Maximum QTcF Changes from Baseline Relative to Placebo

  QTcF1 Change from Baseline
Mean
(Upper 90% Confidence Limit2)
msec
Maximum
(Upper 90% Confidence Limit)
msec
VIBATIV 7.5 mg/kg 4.1 (7) 11.6 (16)
VIBATIV 15 mg/kg 4.6 (8) 15.1 (20)
Positive Control 9.5 (13) 21.6 (26)
1 Fridericia corrected
2 Upper CL from a 2-sided 90% CI on difference from placebo (msec)

ECGs were performed prior to and during the treatment period in patients receiving VIBATIV (telavancin for injection) 10 mg/kg in 3 studies to monitor QTc intervals. In these trials, 214 of 1029 (21%) patients allocated to treatment with VIBATIV (telavancin for injection) and 164 of 1033 (16%) allocated to vancomycin received concomitant medications known to prolong the QTc interval and are known to be associated with definite or possible risk of torsades de pointes. The incidence of QTc prolongation > 60 msec was 1.5% (15 patients) in the VIBATIV (telavancin for injection) group and 0.6% (6 patients) in the vancomycin group. Nine of the 15 VIBATIV (telavancin for injection) patients received concomitant medications known to prolong the QTc interval and definitely or possibly associated with a risk of torsades de pointes, compared with 1 of the 6 patients who received vancomycin. A similar number of patients in each treatment group ( < 1%) who did not receive a concomitant medication known to prolong the QTc interval experienced a prolongation > 60 msec from baseline. In a separate analysis, 1 patient in the VIBATIV (telavancin for injection) group and 2 patients in the vancomycin group experienced QTc > 500 msec. No cardiac adverse events were ascribed to prolongation of the QTc interval.

Pharmacokinetics

The mean pharmacokinetic parameters of telavancin (10mg/kg) after a single and multiple 60-minute intravenous infusions (10 mg/kg every 24 hours) are summarized in Table 6.

Table 6: Pharmacokinetic Parameters of Telavancin in Healthy Adults, 10 mg/kg

  Single Dose Multiple Dose
(n=42) (n=36)
Cmax(mcg/mL) 93.6 ± 14.2 108 ± 26
AUC0-∞ (mcg• hr/mL) 747 ± 129 --1
AUC0-24h (mcg•hr/mL) 666 ± 107 780 ± 125
t½(hr) 8.0 ± 1.5 8.1 ± 1.5
Cl(mL/hr/kg) 13.9 ± 2.9 13.1 ± 2.0
Vss(mL/kg) 145 ± 23 133 ± 24
Cmax maximum plasma concentration
AUC area under concentration-time course
t½ terminal elimination half-life
Cl clearance
Vss apparent volume of distribution at steady state
1
Data not available

In healthy young adults, the pharmacokinetics of telavancin administered intravenously were linear following single doses from 5 to 12.5 mg/kg and multiple doses from 7.5 to 15 mg/kg administered once-daily for up to 7 days. Steady-state concentrations were achieved by the third daily dose.

Distribution

Telavancin binds to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The mean binding is approximately 90% and is not affected by renal or hepatic impairment.

Concentrations of telavancin in skin blister fluid were 40% of those in plasma (AUC0-24hr ratio) after 3 daily doses of 7.5 mg/kg VIBATIV (telavancin for injection) in healthy young adults.

Metabolism

No metabolites of telavancin were detected in in vitro studies using human liver microsomes, liver slices, hepatocytes, and kidney S9 fraction. None of the following recombinant CYP 450 isoforms were shown to metabolize telavancin in human liver microsomes: CYP 1A2, 2C9, 2C19, 2D6, 3A4, 3A5, 4A11. The clearance of telavancin is not expected to be altered by inhibitors of any of these enzymes.

In a mass balance study in male subjects using radiolabeled telavancin, 3 hydroxylated metabolites were identified with the predominant metabolite (THRX-651540) accounting for < 10% of the radioactivity in urine and < 2% of the radioactivity in plasma. The metabolic pathway for telavancin has not been identified.

Excretion

Telavancin is primarily eliminated by the kidney. In a mass balance study, approximately 76% of the administered dose was recovered from urine and < 1% of the dose was recovered from feces (collected up to 216 hours) based on total radioactivity.

Specific Populations

Geriatric Patients

The impact of age on the pharmacokinetics of telavancin was evaluated in healthy young (range 21-42 years) and elderly (range 65-83 years) subjects. The mean CrCl of elderly subjects was 66 mL/min. Age alone did not have a clinically meaningful impact on the pharmacokinetics of telavancin [see Use in Specific Populations].

Pediatric Patients

The pharmacokinetics of telavancin in patients less than 18 years of age have not been studied.

Gender

The impact of gender on the pharmacokinetics of telavancin was evaluated in healthy male (n=8) and female (n=8) subjects. The pharmacokinetics of telavancin were similar in males and females. No dosage adjustment is recommended based on gender.

Renal Impairment

The pharmacokinetics of telavancin were evaluated in subjects with normal and subjects with varying degrees of renal impairment following administration of a single dose of telavancin 7.5 mg/kg (n=28). The mean AUC0-∞- values were approximately 13%, 29%, and 118% higher for subjects with CrCl > 50 to 80 mL/min, CrCl 30 to 50 mL/min, and CrCl ≤ 30 mL/min, respectively, compared to subjects with normal renal function. Dosage adjustment is required in patients with CrCl ≤ 50 mL/min [see DOSAGE AND ADMINISTRATION].

Creatinine clearance was estimated from serum creatinine based on the Cockcroft-Gault formula:

CrCl = [140 – age (years)] x ideal body weight (kg)* /[72 x serum creatinine (mg/dL)] {x 0.85 for female patients}

*Use actual body weight if < ideal body weight (IBW)
IBW (male) = 50 kg + 0.9 kg/cm over 152 cm height
IBW (female) = 45.5 kg + 0.9 kg/cm over 152 cm height

Following administration of a single dose of VIBATIV (telavancin for injection) 7.5 mg/kg to subjects with end-stage renal disease, approximately 5.9% of the administered dose of telavancin was recovered in the dialysate following 4 hours of hemodialysis. The effects of peritoneal dialysis have not been studied.

Following a single intravenous dose of VIBATIV (telavancin for injection) 7.5 mg/kg, the clearance of hydroxypropyl-beta-cyclodextrin was reduced in subjects with renal impairment, resulting in a higher exposure to hydroxypropyl-beta-cyclodextrin. In subjects with mild, moderate, and severe renal impairment, the mean clearance values were 38%, 59%, and 82% lower, respectively, compared to subjects with normal renal function. Multiple infusions of VIBATIV (telavancin for injection) may result in accumulation of hydroxypropyl-beta-cyclodextrin.

Hepatic Impairment

The pharmacokinetics of telavancin were not altered in subjects with moderate hepatic impairment (n= 8, Child-Pugh B) compared to healthy subjects with normal hepatic function matched for gender, age, and weight. The pharmacokinetics of telavancin have not been evaluated in patients with severe hepatic impairment (Child-Pugh C).

Drug Interactions

In Vitro

The inhibitory activity of telavancin against the following CYP 450 enzymes was evaluated in human liver microsomes: CYP 1A2, 2C9, 2C19, 2D6, and 3A4/5. Telavancin inhibited CYP 3A4/5 at potentially clinically relevant concentrations. Upon further evaluation in a Phase 1 clinical trial, telavancin was found not to inhibit the metabolism of midazolam, a sensitive CYP3A substrate (see below).

Midazolam

The impact of telavancin on the pharmacokinetics of midazolam (CYP 3A4/5 substrate) was evaluated in 16 healthy adult subjects following administration of a single dose of VIBATIV (telavancin for injection) 10 mg/kg, intravenous midazolam 1 mg, and both. The results showed that telavancin had no impact on the pharmacokinetics of midazolam and midazolam had no effect on the pharmacokinetics of telavancin. Therefore, telavancin is unlikely to alter the pharmacokinetics of drugs metabolized by the CYP450 system to a clinically significant degree.

Aztreonam

The impact of telavancin on the pharmacokinetics of aztreonam was evaluated in 11 healthy adult subjects following administration of a single dose of VIBATIV 10 mg/kg, aztreonam 2 gm, and both. Telavancin had no impact on the pharmacokinetics of aztreonam and aztreonam had no effect on the pharmacokinetics of telavancin. No dosage adjustment of telavancin or aztreonam is recommended when both drugs are coadministered.

Piperacillin-tazobactam

The impact of telavancin on the pharmacokinetics of piperacillin-tazobactam was evaluated in 12 healthy adult subjects following administration of a single dose of VIBATIV 10 mg/kg, piperacillin-tazobactam 4.5 g, and both. Telavancin had no impact on the pharmacokinetics of piperacillin-tazobactam and piperacillin-tazobactam had no effect on the pharmacokinetics of telavancin. No dosage adjustment of telavancin or piperacillin-tazobactam is recommended when both drugs are coadministered.

Microbiology

Telavancin is a semisynthetic, lipoglycopeptide antibiotic. Telavancin exerts concentration-dependent, bactericidal activity against Gram-positive organisms in vitro, as demonstrated by time-kill assays and MBC/MIC (minimum bactericidal concentration/minimum inhibitory concentration) ratios using broth dilution methodology. In vitro studies demonstrated a telavancin post-antibiotic effect ranging from 1 to 6 hours against S. aureus and other Gram-positive pathogens.

Although telavancin is approximately 90% protein bound, the presence of human serum or human serum albumin has minimal impact on the in vitro activity of telavancin against staphylococci, streptococci, and vancomycin-susceptible enterococci.

Mechanism of Action

Telavancin inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptidoglycan. Telavancin binds to the bacterial membrane and disrupts membrane barrier function.

Interactions with Other Antibacterials

In vitro investigations demonstrated no antagonism between telavancin and amikacin, aztreonam, cefepime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, meropenem, oxacillin, piperacillin/tazobactam, rifampin, and trimethoprim/sulfamethoxazole, when tested in various combinations against telavancin susceptible staphylococci, streptococci, and enterococci. This information is not available for other bacteria.

Cross-Resistance

Some vancomycin-resistant enterococci have a reduced susceptibility to telavancin. There is no known cross-resistance between telavancin and other classes of antibiotics.

Antibacterial Activity

Telavancin has been shown to be active against most isolates of the following microorganisms both in vitro and in clinical infections as described in the Indications and Usage section [see INDICATIONS AND USAGE]:

Facultative Gram-Positive Microorganisms

Staphylococcus aureus (including methicillin-resistant isolates)
Streptococcus pyogenes

Enterococcus faecalis
(vancomycin-susceptible isolates only)
Streptococcus agalactiae

Streptococcus anginosus
group (includes S. anginosus, S. intermedius, and S. constellatus)

Greater than 90% of the following microorganisms exhibit an in vitro MIC less than or equal to the telavancin-susceptible breakpoint for organisms of similar genus shown in Table 7. The safety and effectiveness of telavancin in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

Facultative Gram-Positive Microorganisms

Enterococcus faecium (vancomycin-susceptible isolates only)
Staphylococcus haemolyticus

Streptococcus dysgalactaie
subsp. equisimilis
Staphylococcus epidermidis

Susceptibility Test Methods

When available, the clinical microbiology laboratory should provide cumulative results of the in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.

Dilution technique

Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure [see References]. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of telavancin powder. The MIC values should be interpreted according to the criteria provided in Table 7.

Diffusion technique

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations [see References]. This procedure uses paper disks impregnated with 30 mcg of telavancin to test the susceptibility of microorganisms to telavancin. The disk diffusion interpretive criteria are provided in Table 7.

Table 7 : Susceptibility Interpretive Criteria for Telavancin

  Susceptibility Interpretive Criteria1
Minimal inhibitory
concentration (mcg/mL)
Disk Diffusion zone
diameter(mm)
S I R S I R
Staphylococcus aureus (including methicillin-resistant isolates) ≤ 1 -- -- ≥ 15 -- --
Streptococcus pyogenes ≤ 0.12 -- -- ≥ 15 -- --
Streptococcus agalactiae
Streptococcus anginosus group
Enterococcus faecalis (vancomycin-susceptible isolates only) ≤ 1 -- -- ≥ 15 -- --
1 The current absence of resistant isolates precludes defining any results other than “susceptible” Isolates yielding results other than susceptible should be subjected to additional testing

A report of “susceptible” indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable.

Quality Control

Standardized susceptibility test procedures require the use of laboratory control microorganisms to monitor the performance of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard telavancin powder should provide the range of values noted in Table 8.

Quality control microorganisms are specific strains of organisms with intrinsic biological properties relating to resistance mechanisms and their genetic expression within bacteria; the specific strains used for microbiological quality control are not clinically significant.

Table 8 : Acceptable Quality Control Ranges for Telavancin to be used in Validation of Susceptibility Test Results

  Acceptable Quality Control Ranges
Minimal Inhibitory
Concentration (mcg/mL)
Disk Diffusion Zone
Diameter(mm)
Enterococcus faecalis ATCC 29212 0.12-0.5 Not applicable
Staphylococcus aureus ATCC 29213 0.12-1 Not applicable
Staphylococcus aureus ATCC 25923 Not applicable 16-20
Streptococcus pneumoniae ATCC 496191 0.004-0.03 17-24
1 This organism may be used for validation of susceptibility test results when testing Streptococcus spp. other than S. pneumoniae

Animal Toxicology and/or Pharmacology

Two-week administration of telavancin in rats produced minimal renal tubular vacuolization with no changes in BUN or creatinine. These effects were not seen in studies conducted in dogs for similar duration. Four weeks of treatment resulted in reversible elevations in BUN and/or creatinine in association with renal tubular degeneration that further progressed following 13 weeks of treatment.

These effects occurred at exposures (based on AUCs) that were similar to those measured in clinical trials.

The potential effects of continuous venovenous hemofiltration (CVVH) on the clearance of telavancin were examined in an in vitro model using bovine blood. Telavancin was cleared by CVVH and the clearance of telavancin increased with increasing ultrafiltration rate [see OVERDOSAGE].

Clinical Trials

Complicated Skin and Skin Structure Infections

Adult patients with clinically documented complicated skin and skin structure infections (cSSSI) were enrolled in two randomized, multinational, multicenter, double-blinded trials (Trial 1 and Trial 2) comparing VIBATIV (telavancin for injection) (10 mg/kg IV every 24 hours) with vancomycin (1 g IV every 12 hours) for 7 to 14 days. Vancomycin dosages could be adjusted per site-specific practice. Patients could receive concomitant aztreonam or metronidazole for suspected Gram-negative and anaerobic infection, respectively. These trials were identical in design, enrolling approximately 69% of their patients from the United States.

The trials enrolled adult patients with cSSSI with suspected or confirmed MRSA as the primary cause of infection. The all-treated efficacy (ATe) population included all patients who received any amount of study medication according to their randomized treatment group and were evaluated for efficacy. The clinically evaluable population (CE) included patients in the ATe population with sufficient adherence to the protocol.

The ATe population consisted of 1,794 patients. Of these, 1,410 (78.6%) patients were clinically evaluable (CE). Patients with demographic and baseline characteristics were well-balanced between treatment groups and are presented in Table 9.

Table 9 : Baseline Infection Types in Patients in Trials 1 and 2 – ATe Population

  VIBATIV (telavancin for injection)
(N=884)1
Vancomycin
(N=910)1
Type of infection
Major Abscess 375 (42.4%) 397 (43.6%)
Deep/Extensive Cellulitis 309 (35.0%) 337 (37.0%)
Wound Infection 139 (15.7%) 121 (13.3%)
Infected Ulcer 45 (5.1%) 46 (5.1%)
Infected Burn 16 (1.8%) 9 (1.0%)
1Includes all patients randomized, treated, and evaluated for efficacy

The primary efficacy endpoints in both trials was the clinical cure rates at a follow-up (Test of Cure) visit in the ATe and CE populations. Clinical cure rates in Trials 1 and 2 are displayed for the ATe and CE population in Table 10.

Table 10: Clinical Cure at Test-of-Cure in Trials 1 and 2 - ATe and CE Populations

  Trial 1 Trial 2
VIBATIV
% (n/N)
Vancomycin
% (n/N)
Difference
(95% CI)1
VIBATIV
% (n/N)
Vancomycin
% (n/N)
Difference
(95% CI)1
ATe 72.5% 71.6% 0.9
( -5.3, 7.2)
74.7% 74.0% 0.7
( -5.1, 6.5)
(309/426) (307/429) (342/458) (356/481 )
CE 84.3% 82.8% 1.5
( -4.3, 7.3)
83.9% 87.7% -3.8
( -9.2, 1.5)
(289/343) (288/348) (302/360) (315/359 )
195% CI computed using a continuity correction

The cure rates by pathogen for the microbiologically evaluable (ME) population are presented in Table 11.

Table 11 : Clinical Cure Rates at the Test-of-Cure for the Most Common Pathogens in Trials 1 and 2 – ME Population1

  VIBATIV
% (n/N)
Vancomycin
% (n/N)
Staphylococcus aureus (MRSA) 87.0% 85.9%
(208/239) (225/262)
Staphylococcus aureus (MSSA) 82.0% 85.1%
(132/161) (131/154)
Enterococcus faecalis 95.6% 80.0%
(22/23) (28/35)
Streptococcus pyogenes 84.2% 90.5%
(16/19) (19/21)
Streptococcus agalactiae 73.7% 86.7%
(14/19) (13/15)
Streptococcus anginosus group 76.5% 100.0%
(13/17) (9/9)
1 The ME population included patients in the CE population who had Gram positive pathogens isolated at baseline and had central identification and susceptibility of the microbiological isolate(s)

In the two cSSSI trials, clinical cure rates were similar across gender and race. Clinical cure rates in the telavancin clinically evaluable (CE) population were lower in patients 65 years of age compared to those < 65 years of age. A decrease of this magnitude was not observed in the vancomycin CE population. Clinical cure rates in the telavancin CE population < 65 years of age were 503/581 (86.6%) and in those 65 years were 88/122 (72.1%). In the vancomycin CE population clinical cure rates in patients < 65 years of age were 492/570 (86.3%) and in those 65 years was 111/137 (82.0%). Clinical cure rates in the telavancin-treated patients were lower in patients with baseline CrCl 50 mL/min compared to those with CrCl > 50 mL/min. A decrease of this magnitude was not observed in the vancomycin-treated patients [see WARNINGS AND PRECAUTIONS].

REFERENCES

1. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – 8th ed., CLSI document M7-A8, CLSI, 940 West Valley Rd., Suite 1400, Wayne, PA. 19087-1898, 2009.

2. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests, Approved Standard – 10th ed. CLSI document M2-A10; CLSI, Wayne, PA. 19087-1898, 2009.

3. CLSI. Performance Standards for Antimicrobial Susceptibility Testing - 19th Informational Supplement. CLSI document M100-S19, CLSI, Wayne, PA. 19087-1898, 2009.

Last reviewed on RxList: 9/17/2009
This monograph has been modified to include the generic and brand name in many instances.

PATIENT INFORMATION

MEDICATION GUIDE

VIBATIV
(vy-'ba-tiv)
(telavancin) for Injection

Read this Medication Guide before you start taking VIBATIV (telavancin for injection) and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

What is the most important information I should know about VIBATIV (telavancin for injection) ?

VIBATIV (telavancin for injection) may harm your unborn baby. Women who can become pregnant should have a blood pregnancy test before taking VIBATIV (telavancin for injection) .

  • Talk to your healthcare provider if you are pregnant or plan to become pregnant. Your healthcare provider will decide if VIBATIV (telavancin for injection) is the right medicine for you
  • Do not become pregnant while taking VIBATIV (telavancin for injection) . Women who can become pregnant should use effective birth control (contraception) while taking VIBATIV (telavancin for injection)
  • If you get pregnant while taking VIBATIV (telavancin for injection) , tell your healthcare provider right away
  • If you become pregnant while taking VIBATIV (telavancin for injection) , talk to your healthcare provider about taking part in the VIBATIV (telavancin for injection) Pregnancy Registry. This is a study to learn how VIBATIV (telavancin for injection) affects pregnancy and babies. You can enroll in this registry by calling 1- 888-658-4228

What is VIBATIV (telavancin for injection) ?

VIBATIV (telavancin for injection) is a prescription antibiotic medicine used in adults, alone or with other medicines to treat certain types of germs (bacteria) that cause serious skin infections.

It is not known if VIBATIV (telavancin for injection) is safe or effective in children under 18 years of age.

What should I tell my healthcare provider before taking VIBATIV (telavancin for injection) ?

Before you take VIBATIV (telavancin for injection) , tell your healthcare provider if you:

  • have kidney problems
  • have diabetes
  • have heart problems, including QTC prolongation or a family history of it
  • have high blood pressure
  • have other medical conditions
  • are breastfeeding or plan to breastfeed. It is not known if VIBATIV (telavancin for injection) passes into your breast milk. You and your healthcare provider should decide if you will breastfeed while taking VIBATIV (telavancin for injection)

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. VIBATIV (telavancin for injection) and other medicines can affect each other causing side effects.

Especially tell your healthcare provider if you take:

  • a blood thinner
  • medicine to control your heart rate or rhythm (antiarrhythmics)
  • water pills (diuretics)
  • a Non-Steroidal Anti-Inflammatory Drug (NSAID)
  • certain blood pressure medicines called ACE Inhibitors or ARBs

Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

How will I receive VIBATIV (telavancin for injection) ?

  • VIBATIV (telavancin for injection) is injected into your vein (IV infusion) by your healthcare provider slowly over 1 hour, 1 time a day, for 7 to 14 days.
  • Do not stop taking VIBATIV (telavancin for injection) unless your healthcare provider tells you to even if you feel better.
  • It is important that you receive all of your VIBATIV (telavancin for injection) doses. Do not skip any doses.
  • If you miss a dose or stop taking VIBATIV (telavancin for injection) before getting all of your doses, contact your healthcare provider right away.
  • If you skip doses or stop treatment too soon, the germs (bacteria) may grow again and VIBATIV (telavancin for injection) may not work.
  • Your healthcare provider will do tests before you start and while you take VIBATIV (telavancin for injection) .

What are the possible side effects of VIBATIV (telavancin for injection) ?

VIBATIV (telavancin for injection) may cause serious side effects, including:

See "What is the most important information I should know about VIBATIV (telavancin for injection) ?"

  • Kidney problems
  • Infusion-related reactions. Infusion-related reactions can include: red color (flushing) to your upper body, hives (raised bumps), itching or rash if VIBATIV (telavancin for injection) is given too fast
  • Intestine infection. Intestine infections can cause diarrhea or bloody stools, stomach cramps, and a fever. These infections can happen 2 or more months after you stop taking VIBATIV (telavancin for injection)
  • Irregular heartbeat.
  • Changes in blood and urine test. Tell your healthcare provider if you plan to have any test of your blood or urine while taking VIBATIV (telavancin for injection)

Call your healthcare provider right away if you have any of the serious side effects listed above.

The most common side effects of VIBATIV (telavancin for injection) include:

  • change in your sense of taste
  • nausea
  • vomiting
  • foamy urine

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of VIBATIV (telavancin for injection) . For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

How should I store VIBATIV (telavancin for injection) ?

  • Store VIBATIV (telavancin for injection) in the original package
  • Keep VIBATIV (telavancin for injection) refrigerated between 350F to 460F (20C to 80C)
  • Keep out of heat

Keep VIBATIV (telavancin for injection) and all medicines out of the reach of children.

General Information about the safe and effective use of VIBATIV (telavancin for injection) .

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VIBATIV (telavancin for injection) for a condition for which it is not prescribed. Do not give VIBATIV (telavancin for injection) to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about VIBATIV (telavancin for injection) . If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about VIBATIV (telavancin for injection) that is written for health professionals.

For more information, go to www.vibativ (telavancin for injection) .com or call 1-800-727-7003.

What are the ingredients in VIBATIV?

Active ingredient: telavancin hydrochloride

Inactive ingredients: hydroxypropylbetadex, Ph. Eur (hydroxypropyl-beta-cyclodextrin), mannitol, sodium hydroxide, and hydrochloric acid

This Medication Guide has been approved by the U.S. Food and Drug Administration August 2009

VIBATIV
(telavancin)
[Lipoglycopeptide]
Theravance, Inc. 901 Gateway Boulevard, South San Francisco, CA 94080. [650-808-6076]

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOALS

The goal of the VIBATIV (telavancin for injection) REMS is to avoid unintended exposure of pregnant women to VIBATIV (telavancin for injection) by:

  • Educating healthcare professionals (HCPs) and patients on the potential risk of fetal developmental toxicity if women are exposed to VIBATIV (telavancin for injection) while pregnant.
  • Informing HCPs that a serum pregnancy test should be performed before initiating therapy with VIBATIV (telavancin for injection) in women of childbearing potential.
  • Informing HCPs that women of childbearing potential, including those being treated in the outpatient setting, should be counseled about pregnancy prevention and use of effective contraception during VIBATIV (telavancin for injection) use.
  • Informing HCPs and patients about the Pregnancy Registry for patients exposed to VIBATIV (telavancin for injection) during pregnancy.

II. REMS ELEMENTS

A. Medication Guide

Theravance will ensure that a Medication Guide will be distributed with each VIBATIV (telavancin for injection) prescription in accordance with 21 CFR 208.24. VIBATIV (telavancin for injection) is packaged as a single unit of use and the Medication Guide is inserted inside the carton.

Additional copies of the Medication Guide will also be available via sales and/or clinical representatives, the product website, and by request at 1-800-7277003.

Please see appended Medication Guide.

B. Communication Plan

In accordance with FDCA 505-1(e)(3), Theravance will implement a communication plan to targeted healthcare providers and pharmacists to support the implementation of the VIBATIV (telavancin for injection) REMS. The communication plan consists of the following:

1. A Dear Healthcare Provider (HCP) Letter describing the fetal effects of VIBATIV (telavancin for injection) seen in animals and pregnancy prevention measures. The letter will include Pregnancy Registry Information. The letter will be accompanied by the VIBATIV (telavancin for injection) Package Insert (PI) and the Medication Guide.

2. The Dear HCP Letter will be distributed to targeted HCPs and pharmacists at the specified timeframes:

  1.  Prior to commercial distribution
  2.  6 months after product approval
  3.  1 and 2 years after product approval

3. The Dear HCP Letter will be distributed either through hardcopy mailings by U.S. mail or email to reach the target audience. The letter will also be available on the product website. The website will also include information about the Pregnancy Registry and the toll-free number to call to enroll in the Registry.

The email will target physicians based on the American Medical Association database. The email distribution list for other healthcare providers will be based on other databases and secured through a private contractor.

Providers that have an email address on file will receive the Dear HCP Letter via email. If the intended recipient does not open the Dear HCP Letter within 72 hours, the materials will be distributed hardcopy via U.S. mail. The healthcare providers on the target audience list who do not have an email on file will receive a hardcopy via U.S. mail.

All distributions, hardcopy and electronic will include the designation "Important Drug Warning" according to 21 CFR 200.5.

4. The Dear HCP Letter will be sent to the following targeted Healthcare Providers:

Physician Groups
Infectious Disease
Emergency Medicine
Critical Care Medicine
Hospitalist
General Surgery
Obstetrics and Gynecology
Family Practice

Other Healthcare Professionals
Health System Pharmacists / Hospital Pharmacists
Outpatient Infusion Providers

Organizational Headquarters
Infectious Disease Society of America
American College of Emergency Physicians

Last reviewed on RxList: 9/17/2009
This monograph has been modified to include the generic and brand name in many instances.

>

PATIENT INFORMATION

MEDICATION GUIDE

VIBATIV
(vy-'ba-tiv)
(telavancin) for Injection

Read this Medication Guide before you start taking VIBATIV (telavancin for injection) and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

What is the most important information I should know about VIBATIV (telavancin for injection) ?

VIBATIV (telavancin for injection) may harm your unborn baby. Women who can become pregnant should have a blood pregnancy test before taking VIBATIV (telavancin for injection) .

  • Talk to your healthcare provider if you are pregnant or plan to become pregnant. Your healthcare provider will decide if VIBATIV (telavancin for injection) is the right medicine for you
  • Do not become pregnant while taking VIBATIV (telavancin for injection) . Women who can become pregnant should use effective birth control (contraception) while taking VIBATIV (telavancin for injection)
  • If you get pregnant while taking VIBATIV (telavancin for injection) , tell your healthcare provider right away
  • If you become pregnant while taking VIBATIV (telavancin for injection) , talk to your healthcare provider about taking part in the VIBATIV (telavancin for injection) Pregnancy Registry. This is a study to learn how VIBATIV (telavancin for injection) affects pregnancy and babies. You can enroll in this registry by calling 1- 888-658-4228

What is VIBATIV (telavancin for injection) ?

VIBATIV (telavancin for injection) is a prescription antibiotic medicine used in adults, alone or with other medicines to treat certain types of germs (bacteria) that cause serious skin infections.

It is not known if VIBATIV (telavancin for injection) is safe or effective in children under 18 years of age.

What should I tell my healthcare provider before taking VIBATIV (telavancin for injection) ?

Before you take VIBATIV (telavancin for injection) , tell your healthcare provider if you:

  • have kidney problems
  • have diabetes
  • have heart problems, including QTC prolongation or a family history of it
  • have high blood pressure
  • have other medical conditions
  • are breastfeeding or plan to breastfeed. It is not known if VIBATIV (telavancin for injection) passes into your breast milk. You and your healthcare provider should decide if you will breastfeed while taking VIBATIV (telavancin for injection)

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. VIBATIV (telavancin for injection) and other medicines can affect each other causing side effects.

Especially tell your healthcare provider if you take:

  • a blood thinner
  • medicine to control your heart rate or rhythm (antiarrhythmics)
  • water pills (diuretics)
  • a Non-Steroidal Anti-Inflammatory Drug (NSAID)
  • certain blood pressure medicines called ACE Inhibitors or ARBs

Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

How will I receive VIBATIV (telavancin for injection) ?

  • VIBATIV (telavancin for injection) is injected into your vein (IV infusion) by your healthcare provider slowly over 1 hour, 1 time a day, for 7 to 14 days.
  • Do not stop taking VIBATIV (telavancin for injection) unless your healthcare provider tells you to even if you feel better.
  • It is important that you receive all of your VIBATIV (telavancin for injection) doses. Do not skip any doses.
  • If you miss a dose or stop taking VIBATIV (telavancin for injection) before getting all of your doses, contact your healthcare provider right away.
  • If you skip doses or stop treatment too soon, the germs (bacteria) may grow again and VIBATIV (telavancin for injection) may not work.
  • Your healthcare provider will do tests before you start and while you take VIBATIV (telavancin for injection) .

What are the possible side effects of VIBATIV (telavancin for injection) ?

VIBATIV (telavancin for injection) may cause serious side effects, including:

See "What is the most important information I should know about VIBATIV (telavancin for injection) ?"

  • Kidney problems
  • Infusion-related reactions. Infusion-related reactions can include: red color (flushing) to your upper body, hives (raised bumps), itching or rash if VIBATIV (telavancin for injection) is given too fast
  • Intestine infection. Intestine infections can cause diarrhea or bloody stools, stomach cramps, and a fever. These infections can happen 2 or more months after you stop taking VIBATIV (telavancin for injection)
  • Irregular heartbeat.
  • Changes in blood and urine test. Tell your healthcare provider if you plan to have any test of your blood or urine while taking VIBATIV (telavancin for injection)

Call your healthcare provider right away if you have any of the serious side effects listed above.

The most common side effects of VIBATIV (telavancin for injection) include:

  • change in your sense of taste
  • nausea
  • vomiting
  • foamy urine

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of VIBATIV (telavancin for injection) . For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

How should I store VIBATIV (telavancin for injection) ?

  • Store VIBATIV (telavancin for injection) in the original package
  • Keep VIBATIV (telavancin for injection) refrigerated between 350F to 460F (20C to 80C)
  • Keep out of heat

Keep VIBATIV (telavancin for injection) and all medicines out of the reach of children.

General Information about the safe and effective use of VIBATIV (telavancin for injection) .

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VIBATIV (telavancin for injection) for a condition for which it is not prescribed. Do not give VIBATIV (telavancin for injection) to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about VIBATIV (telavancin for injection) . If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about VIBATIV (telavancin for injection) that is written for health professionals.

For more information, go to www.vibativ (telavancin for injection) .com or call 1-800-727-7003.

What are the ingredients in VIBATIV?

Active ingredient: telavancin hydrochloride

Inactive ingredients: hydroxypropylbetadex, Ph. Eur (hydroxypropyl-beta-cyclodextrin), mannitol, sodium hydroxide, and hydrochloric acid

This Medication Guide has been approved by the U.S. Food and Drug Administration August 2009

VIBATIV
(telavancin)
[Lipoglycopeptide]
Theravance, Inc. 901 Gateway Boulevard, South San Francisco, CA 94080. [650-808-6076]

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOALS

The goal of the VIBATIV (telavancin for injection) REMS is to avoid unintended exposure of pregnant women to VIBATIV (telavancin for injection) by:

  • Educating healthcare professionals (HCPs) and patients on the potential risk of fetal developmental toxicity if women are exposed to VIBATIV (telavancin for injection) while pregnant.
  • Informing HCPs that a serum pregnancy test should be performed before initiating therapy with VIBATIV (telavancin for injection) in women of childbearing potential.
  • Informing HCPs that women of childbearing potential, including those being treated in the outpatient setting, should be counseled about pregnancy prevention and use of effective contraception during VIBATIV (telavancin for injection) use.
  • Informing HCPs and patients about the Pregnancy Registry for patients exposed to VIBATIV (telavancin for injection) during pregnancy.

II. REMS ELEMENTS

A. Medication Guide

Theravance will ensure that a Medication Guide will be distributed with each VIBATIV (telavancin for injection) prescription in accordance with 21 CFR 208.24. VIBATIV (telavancin for injection) is packaged as a single unit of use and the Medication Guide is inserted inside the carton.

Additional copies of the Medication Guide will also be available via sales and/or clinical representatives, the product website, and by request at 1-800-7277003.

Please see appended Medication Guide.

B. Communication Plan

In accordance with FDCA 505-1(e)(3), Theravance will implement a communication plan to targeted healthcare providers and pharmacists to support the implementation of the VIBATIV (telavancin for injection) REMS. The communication plan consists of the following:

1. A Dear Healthcare Provider (HCP) Letter describing the fetal effects of VIBATIV (telavancin for injection) seen in animals and pregnancy prevention measures. The letter will include Pregnancy Registry Information. The letter will be accompanied by the VIBATIV (telavancin for injection) Package Insert (PI) and the Medication Guide.

2. The Dear HCP Letter will be distributed to targeted HCPs and pharmacists at the specified timeframes:

  1.  Prior to commercial distribution
  2.  6 months after product approval
  3.  1 and 2 years after product approval

3. The Dear HCP Letter will be distributed either through hardcopy mailings by U.S. mail or email to reach the target audience. The letter will also be available on the product website. The website will also include information about the Pregnancy Registry and the toll-free number to call to enroll in the Registry.

The email will target physicians based on the American Medical Association database. The email distribution list for other healthcare providers will be based on other databases and secured through a private contractor.

Providers that have an email address on file will receive the Dear HCP Letter via email. If the intended recipient does not open the Dear HCP Letter within 72 hours, the materials will be distributed hardcopy via U.S. mail. The healthcare providers on the target audience list who do not have an email on file will receive a hardcopy via U.S. mail.

All distributions, hardcopy and electronic will include the designation "Important Drug Warning" according to 21 CFR 200.5.

4. The Dear HCP Letter will be sent to the following targeted Healthcare Providers:

Physician Groups
Infectious Disease
Emergency Medicine
Critical Care Medicine
Hospitalist
General Surgery
Obstetrics and Gynecology
Family Practice

Other Healthcare Professionals
Health System Pharmacists / Hospital Pharmacists
Outpatient Infusion Providers

Organizational Headquarters
Infectious Disease Society of America
American College of Emergency Physicians

Last reviewed on RxList: 9/17/2009
This monograph has been modified to include the generic and brand name in many instances.

Disclaimer

Vibativ Consumer

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

TELAVANCIN - INJECTION

(TEL-a-VAN-sin)

COMMON BRAND NAME(S): Vibativ

WARNING: This drug may cause harm to an unborn baby if used during pregnancy. Women of childbearing age should have a pregnancy test before starting this medication. It is important to prevent pregnancy while using this medication. Consult your doctor for more details and to discuss the use of reliable forms of birth control while using this medication. If you become pregnant or think you may be pregnant, tell your doctor immediately.

USES: This medication is an antibiotic used to treat serious bacterial infections of the skin. It works by stopping the growth of bacteria.

HOW TO USE: Read the Medication Guide provided by your pharmacist before you start using telavancin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

This medication is given by injection into a vein as directed by your doctor, usually once a day. It should be injected slowly over 60 minutes. The dosage and length of treatment is based on your weight, medical condition, and response to treatment.

If you are giving this medication to yourself at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.

Antibiotics work best when the amount of medicine in your body is kept at a constant level. Therefore, use this drug at evenly spaced intervals.

Continue to use this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may allow bacteria to continue to grow, which may result in a return of the infection.

Tell your doctor if your condition persists or worsens.

Disclaimer

Vibativ Consumer (continued)

SIDE EFFECTS: Flushing of the upper body may occur if this medication is injected too fast ("red man syndrome"). Tell your doctor immediately if this occurs. The infusion of this medication may need to be slowed or stopped.

Metallic/soapy taste, nausea, vomiting, or foamy urine may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: change in the amount of urine.

Get medical help right away if any of these rare but serious side effects occur: fast/irregular heartbeat, severe dizziness, fainting.

This medication may rarely cause a severe intestinal condition (Clostridium difficile-associated diarrhea) due to a type of resistant bacteria. This condition may occur during treatment or weeks to months after treatment has stopped. Do not use anti-diarrhea products or narcotic pain medications if you have any of the following symptoms because these products may make them worse. Tell your doctor immediately if you develop: persistent diarrhea, abdominal or stomach pain/cramping, blood/mucus in your stool.

Use of this medication for prolonged or repeated periods may result in oral thrush or a new vaginal yeast infection. Contact your doctor if you notice white patches in your mouth, a change in vaginal discharge, or other new symptoms.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any of the following symptoms of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the Vibativ (telavancin for injection) Side Effects Center for a complete guide to possible side effects »

PRECAUTIONS: Before using telavancin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, diabetes, high blood pressure (hypertension).

Telavancin may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can infrequently result in serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that require immediate medical attention. The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may affect the heart rhythm (see also Drug Interactions section). Before using telavancin, tell your doctor or pharmacist if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).

Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using telavancin safely.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

Telavancin may cause live bacterial vaccines (such as typhoid vaccine) not to work as well. Therefore, do not have any immunizations/vaccinations while using this medication without the consent of your doctor.

This medication is not recommended for use during pregnancy. It may harm an unborn baby. Consult your doctor for more details. (See also Warning section.)

It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.

Disclaimer

Vibativ Consumer (continued)

DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.

Some products that may interact with this drug include: other drugs that may affect the kidneys (including NSAIDs such as ibuprofen).

Many drugs besides telavancin may affect the heart rhythm (QT prolongation), including amiodarone, dofetilide, pimozide, procainamide, quinidine, sotalol, macrolide antibiotics (such as erythromycin), among others.

Although most antibiotics probably do not affect hormonal birth control such as pills, patch, or ring, some antibiotics may decrease their effectiveness. This could cause pregnancy. Examples include rifamycins such as rifampin or rifabutin. Be sure to ask your doctor or pharmacist if you should use additional reliable birth control methods while using this antibiotic.

This medication may interfere with certain laboratory tests (including coagulation tests such as PT/INR/APPT, urine protein tests), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.

OVERDOSE: If overdose is suspected, contact a poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: Laboratory and/or medical tests (such as kidney function) may be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

MISSED DOSE: For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor or pharmacist immediately to establish a new dosing schedule. Do not double the dose to catch up.

STORAGE: Consult the product instructions and your pharmacist for storage details. Keep all medications away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

Information last revised October 2011. Copyright(c) 2011 First Databank, Inc.

Vibativ Patient Information Including Side Effects

Brand Names: Vibativ

Generic Name: telavancin (Pronunciation: TEL a VAN sin)

What is telavancin (Vibativ)?

Telavancin is an antibiotic that treats infection caused by bacteria.

Telavancin is used to treat severe skin infections.

Telavancin may also be used for other purposes not listed in this medication guide.

What are the possible side effects of telavancin (Vibativ)?

Some people receiving a telavancin injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your doctor right away if you feel itchy or tingly, or have a red rash on your upper body during the injection.

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • diarrhea that is watery or bloody;
  • drowsiness, confusion, mood changes, increased thirst, loss of appetite, nausea and vomiting;
  • swelling, weight gain, feeling short of breath; or
  • urinating less than usual or not at all.

Less serious side effects may include:

  • nausea, vomiting, diarrhea, stomach pain, loss of appetite;
  • chills or shivering;
  • headache, dizziness;
  • foamy appearance in your urine;
  • unusual or unpleasant taste in your mouth;
  • vaginal itching or discharge;
  • mild skin rash or itching; or
  • redness or pain around the IV needle.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Vibativ (telavancin for injection) Side Effects Center for a complete guide to possible side effects »

What is the most important information I should know about telavancin (Vibativ)?

Before using this medication, tell your doctor if you are pregnant. You may need a pregnancy test to determine whether you are pregnant before you start using telavancin.

If you are not pregnant before you start using telavancin, use effective birth control to prevent pregnancy during treatment. Any woman who could possibly become pregnant should use birth control during treatment with telavancin.

If you are a woman using telavancin, you are considered able to become pregnant unless you have ovarian failure, have had a tubal ligation or hysterectomy, or have been in menopause or not had a menstrual period in 2 years.

Telavancin can be harmful to the kidneys, and this effect is increased when telavancin is used together with other medicines that can harm the kidneys. Before using telavancin, tell your doctor if you are receiving chemotherapy, or using medicines to treat a bowel disorder, medication to prevent organ transplant rejection, antiviral medications, pain or arthritis medicines, a diuretic (water pill), or any other injected antibiotics.

If you have kidney disease, you may need a dose adjustment or special tests to safely use telavancin.

Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Telavancin will not treat a viral infection such as the common cold or flu.

Call your doctor right away if you have a serious side effect such as watery or bloody diarrhea, confusion, thirst, swelling, feeling short of breath, or urinating less than usual or not at all

Side Effects Centers

Vibativ Patient Information including How Should I Take

What should I discuss with my health care provider before using telavancin (Vibativ)?

You should not use this medication if you are allergic to it.

If you have kidney disease, you may need a dose adjustment or special tests to safely use telavancin.

FDA pregnancy category C. It is not known whether telavancin is harmful to an unborn baby. Before using this medication, tell your doctor if you are pregnant. You may need a pregnancy test to determine whether you are pregnant before you start using telavancin.

Your name may need to be listed on a pregnancy registry if you use telavancin while you are pregnant. The purpose of this registry is to track the outcome of the pregnancy and delivery to evaluate whether telavancin had any effect on the baby.

If you are not pregnant before you start using telavancin, use effective birth control to prevent pregnancy during treatment. Any woman who could possibly become pregnant should use birth control during treatment with telavancin.

If you are a woman using telavancin, you are considered able to become pregnant unless you have ovarian failure, have had a tubal ligation or hysterectomy, or have been in menopause or not had a menstrual period in 2 years.

It is not known whether telavancin passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How is telavancin given (Vibativ)?

Telavancin is given as an injection through a needle placed into a vein. Your doctor, nurse, or other healthcare provider will give you this injection. You may be shown how to use your medicine at home. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of needles, IV tubing, and other items used in giving the medicine.

Telavancin must be given slowly through an IV infusion, and can take at least 1 hour to complete.

This medication is usually given once every 24 hours for 7 to 14 days. Follow your doctor's instructions.

Telavancin powder must be mixed with a liquid (diluent) before using it. If you are using the injections at home, be sure you understand how to properly mix and store the medication.

Each single-use vial (bottle) of this medicine is for one use only. Throw away the vial after one use, even if there is still some medicine left in it after injecting your dose.

Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Telavancin will not treat a viral infection such as the common cold or flu.

To be sure this medication is not causing harmful effects, your kidney function will need to be checked with blood tests on a regular basis. Do not miss any follow-up visits to your doctor.

Telavancin can cause you to have unusual results with certain medical tests. Tell any doctor who treats you that you are using telavancin.

Store telavancin powder in the refrigerator. Do not freeze.

After mixing telavancin with a diluent, you may store the mixture in the refrigerator and use it within 72 hours. Do not freeze.

Mixed medicine may also be stored at room temperature, but you must then use it within 4 hours after mixing.

Do not use the mixed medication if it has changed colors or has any particles in it. Mix a new dose.

Side Effects Centers

Vibativ Patient Information including If I Miss a Dose

What happens if I miss a dose (Vibativ)?

Contact your doctor for instructions if you miss a dose of this medication.

What happens if I overdose (Vibativ)?

Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include confusion, increased thirst, vomiting, swelling, and urinating less than usual or not at all.

What should I avoid while using telavancin (Vibativ)?

Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or has blood in it, stop taking this medication and call your doctor. Do not use any medicine to stop the diarrhea unless your doctor has told you to.

What other drugs will affect telavancin (Vibativ)?

Telavancin can be harmful to the kidneys, and this effect is increased when telavancin is used together with other medicines that can harm the kidneys. Before using telavancin, tell your doctor if you are receiving chemotherapy, or using medicines to treat a bowel disorder, medication to prevent organ transplant rejection, antiviral medications, pain or arthritis medicines, a diuretic (water pill), or any other injected antibiotics.

Tell your doctor about all other medications you use, especially:

  • arsenic trioxide (Trisenox);
  • droperidol (Inapsine);
  • an antibiotic such as clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin), levofloxacin (Levaquin), moxifloxacin (Avelox), or pentamidine (NebuPent, Pentam);
  • an antidepressant such as amitriptylline (Elavil, Vanatrip), clomipramine (Anafranil), or desipramine (Norpramin);
  • anti-malaria medications such as chloroquine (Arelan), or mefloquine (Lariam);
  • heart rhythm medicine such as amiodarone (Cordarone, Pacerone), dofetilide (Tikosyn), disopyramide (Norpace), ibutilide (Corvert), procainamide (Procan, Pronestyl), propafenone (Rythmol), quinidine (Quinidex, Quin-Release Quin-G), or sotalol (Betapace);
  • medicine to prevent or treat nausea and vomiting, such as dolasetron (Anzemet) or ondansetron (Zofran);
  • medicines to treat psychiatric disorders, such as chlorpromazine (Thorazine), clozapine (FazaClo, Clozaril), haloperidol (Haldol), pimozide (Orap), thioridazine (Mellaril), or ziprasidone (Geodon);
  • migraine headache medicine such as sumatriptan (Imitrex) or zolmitriptan (Zomig); or
  • narcotic medication such as levomethadyl (Orlaam), or methadone (Dolophine, Methadose).

This list is not complete and there may be other drugs that can interact with telavancin. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about telavancin.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 1.03. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com